Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).
Ramaprasad Srinivasan
Research Funding - GlaxoSmithKline
Donald P. Bottaro
Research Funding - GlaxoSmithKline
Toni K. Choueiri
Research Funding - GlaxoSmithKline
* Ulka N. Vaishampayan
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Jonathan E. Rosenberg
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Theodore Logan
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Andrea Lynne Harzstark
Research Funding - GlaxoSmithKline
Brian I. Rini
Research Funding - GlaxoSmithKline
Sandy Srinivas
Research Funding - GlaxoSmithKline
Laurel M. Adams
Employment or Leadership Position - GK Oncology R&D
Stock Ownership - GlaxoSmithKline
Kevin Laubscher
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Lone Harild Ottesen
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline (B)
David F. McDermott
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
W. Marston Linehan
Research Funding - GlaxoSmithKline